FDA
-
-
-
-
-
-
-
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
-
-
-
-
-
-
-
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
-
-
-
-
-
-
-
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Lexaria Bioscience (LEXX) Unveils Planned 2024 GLP-1 Study Program
-
-
-
-
-
-
-
Lexaria (LEXX) Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
-
-
-
-
-
-
-
Lexaria Bioscience (LEXX) Provides Update on Investigational New Drug Application Progress
-
-
-
-
-
-
-
Lexaria Bioscience (LEXX) Reports Publication of Research into DehydraTECH-CBD
-
251,775 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All